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ABSTRACT 
The purpose of this investigation is to present an overview of roadside drug driving 
enforcement and detections in Queensland, Australia since the introduction of oral fluid 
screening. Drug driving is a problematic issue for road safety and investigations of the 
prevalence and impact of drug driving suggest that, in particular, the use of illicit drugs may 
increase a driver’s involvement in a road crash when compared to a driver who is drug free. 
In response to the potential increased crash involvement of drug impaired drivers, Australian 
police agencies have adopted the use of oral fluid analysis to detect the presence of illicit 
drugs in drivers. This paper describes the results of roadside drug testing for over 80,000 
drivers in Queensland, Australia, from December 2007 to June 2012.  It provides unique data 
on the prevalence of methamphetamine, cannabis and ecstasy in the screened population for 
the period.  When prevalence rates are examined over time, drug driving detection rates have 
almost doubled from around 2.0% at the introduction of roadside testing operations to just 
under 4.0% in the latter years.  The most common drug type detected was methamphetamine 
(40.8%) followed by cannabis (29.8%) and methamphetamine/cannabis combination 
(22.5%). By comparison, the rate of ecstasy detection was very low (1.7%).  The data 
revealed a number of regional, age and gender patterns and variations of drug driving across 
the state.  Younger drivers were more likely to test positive for cannabis whilst older drivers 
were more likely to test positive for methamphetamine.  The overall characteristics of drivers 
who tested positive to the presence of at least one of the target illicit drugs are they are likely 
to be male, aged 30-39 years, be driving a car on Friday, Saturday or Sunday between 
6:00PM and 6:00AM and to test positive for methamphetamine. 
Keywords: Drug driving; roadside drug testing; enforcement.
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1. Introduction 
Drug driving is a problematic issue for road safety in many jurisdictions around the 
world. Over the past decade, a considerable body of research has focused on ascertaining the 
prevalence and impact of driving under the influence of drugs (e.g., Albery et al., 2000; 
Drummer et al., 2003; Kuypers et al., 2012). Assessment of drug involvement for drivers 
involved in fatal and non- fatally injured vehicle crashes has provided an indication of the 
prevalence of drug driving. For example, the presence of drugs in bodily fluid of fatally 
injured drivers has been shown to range between 8.8% and 39.6% (del Rı́o et al., 2002; 
Drummer et al., 2003; Drummer et al., 2004; Mura et al., 2006; Swann, Boorman, and 
Papafotiou, 2004) and between 2.7% and 41.3% for non-fatally injured drivers (Athanaselis 
et al., 1999; Longo et al., 2000). Investigations of the prevalence and impact of drug driving 
suggest that, in particular, the use of illicit drugs may increase a driver’s involvement in a 
road crash when compared to a driver who is drug free. For example, Drummer et al. (2004) 
found that among a large sample of fatally-injured drivers, those who tested positive to the 
active constituent in cannabis (Delta-9-tetrahydrocannabinol [THC]) at 5ng/ml or greater 
were 6.6 times more likely to be culpable for a road crash than a drug free driver (95% CI OR 
1.5-28.0). This finding is on par with the culpability of a driver with a blood alcohol 
concentration (BAC) of 0.15% or greater being involved in a crash compared to a driver with 
a BAC of 0.0%.  
In response to the potential increased crash involvement of drug impaired drivers, 
Australian police agencies have adopted the use of oral fluid analysis to detect the presence 
of illicit drugs in drivers. This implementation has offered a unique opportunity to examine 
the incidence and characteristics of drug driving across the community via the examination of 
large data sets. Numerous studies have shown that oral fluid testing is useful in detecting very 
recent drug use (Dolan, Rouen, and Kimber, 2004; Drummer et al., 2007; Walsh et al., 2004) 
and correlates reasonably well with blood concentrations (Toennes et al., 2005). 
Results from roadside drug testing have revealed similar rates to those obtained from 
fatal and non-fatally injured drivers. For instance, one investigation revealed that among a 
random sample of non-crash involved drivers from Britain, 4.7% tested positive to the 
presence of a drug (Buttress et al., 2004).  Wylie et al. (2005) found that among a German 
sample, 16.8% of drivers tested positive for at least one drug.  
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In Australia, Drummer et al. (2007) undertook an examination of drugs in oral fluid 
for over 13,000 Victorian drivers randomly tested for the presence of THC and 
methamphetamines and reported the overall drug positive rate to be 2.4% of the screened 
population. Similar findings were reported by Davey, Leal, and Freeman (2007) where they 
found 3.5% of the screened driving population tested positive to at least one illicit drug in 
rural Queensland, while Davey and Freeman (2009) found 3.7% in urban Queensland. 
Research from South Australia has reported an overall detection rate of 2.9% (see Thompson,  
2008; Thompson, 2012) whereas examination of roadside drug testing in Western Australia 
reported a positive detection rate of 5.3% (Woolley and Baldock, 2009), while in New South 
Wales it has remained constant at 2.0% (Papafotiou and Boorman, 2011; Rowden et al., 
2011).  
 In 2004, Victoria was the first Australian jurisdiction to implement a legislative 
framework to allow police to randomly stop drivers and collect a roadside oral fluid sample 
to assist in laying a drug driving charge. The purpose of this legislation is to provide police 
with an immediate roadside strategy for interdiction. More importantly, and in line with 
general Australian policing strategies for random breath alcohol testing, roadside oral fluid 
testing offers a platform for an effective on going deterrence strategy (Papafotiou and 
Boorman, 2011; Drummer et al., 2007). Roadside oral fluid drug testing programs have now 
been adopted by all Australian policing jurisdictions (see Table 1), with Queensland 
implementing roadside drug testing for methamphetamine (MA), 3,4-methylenediox-
methamphetamine (MDMA), and cannabis (delta-9-tetrahydrocannabinol, THC) in 
December 2007. In Queensland, the penalty if detected via a roadside drug test is detailed in 
S79 (2AA) of the Transport Operations (Road Use Management) Act 1995 (Qld), which 
states a person is liable to a penalty not exceeding 14 penalty units ($110 AUD per penalty 
unit) or to imprisonment for a term not exceeding three months. As such, the maximum 
monetary penalty is currently $1,540 AUD with possible loss of licence for up to nine months 
for a first offence.  
This paper describes the results of roadside drug testing for over 80,000 drivers in 
Queensland, Australia, from December 2007 to June 2012. It provides unique data on the 
prevalence of MA, THC and MDMA in the screened population for the period.   
2. Method 
2.1. Participants 
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The dataset contains information for all drivers stopped and processed as part of the 
Queensland roadside drug driving legislative framework from December 2007 to June 2012 
(N = 80,624). The data collection occurred within the state’s eight defined policing regions, 
covering the total Queensland population of 4,524,529 (see Table 3). The dataset was deemed 
exempt from the need for University Human Research Ethics Committee review, approval 
and monitoring in conformity with sections 5.1.22 and 5.1.23 of the National Statement on 
Ethical Conduct in Human Research (2007).  
2.2. Roadside testing procedure  
In Queensland, the drug screening process consists of two stages roadside as well as 
confirmatory analysis by the Queensland Government forensic laboratory. The first roadside 
stage involves a trained police officer intercepting a driver who undertakes a preliminary 
screen test using the Securetec DrugWipe II Twin oral fluid device. This test takes 
approximately five minutes to complete for MA, MDMA and THC. If the test results indicate 
a ‘non positive’ outcome, the driver is no longer detained. However, if the test indicates a 
positive result (on any of the screened drugs), the driver is requested to provide a second 
sample of oral fluid using the Cozart DDS805 2-panel methamphetamine/ THC test with 
Cozart DDS Reader DDS202S. If this test indicates the presence of one or more of the three 
legislated drugs (or the driver refuses or fails to provide an oral fluid sample), then the 
individual’s driver licence is suspended for a period of 24 hours. Under the legislation all 
positive roadside oral fluid samples are then sent to the Queensland Government forensic 
laboratory for confirmation. It is from this laboratory analysis and confirmation that a charge 
of drug driving is issued.  
Data relating to the number of operations and tests conducted are compiled regularly 
by the Queensland Police Service. For the purposes of this investigation, information relating 
to age, gender, vehicle type, and outcome of the confirmatory test from the Queensland 
Government laboratory were compiled for all drivers who tested positive using Cozart 
DDS805 2-panel methamphetamine/THC test with Cozart DDS Reader DDS202S at the 
roadside.  
3. Results 
3.1. Detection rate  
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In the period 1 December 2007 to 30 June 2012, 80,624 tests were conducted, with 
2,139 positive detections at the roadside. However, 10 cases were later identified by the 
Queensland Government forensic laboratory as false positives, equating to 0.01% of total 
tests. As such, the total number of confirmed detections was N = 2,129 (2.7%).  
Examination of the number of roadside tests conducted each year showed the greatest 
number of positive detections occurred in 2011 (see Table 2). It should be noted that 2007 
and 2012 are not complete calendar years. Further, in 2011, the number of roadside tests 
more than doubled from the number conducted in 2009 and rose 16.0% compared to the 
number conducted in 2010. Table 2 also outlines the detection rate for each year which shows 
an increase in recent years, up from 1:50 in 2008 to 1:26 in 2012. It is interesting to note that 
the overall detection rate for oral fluid testing (1:38) is higher than alcohol breath testing 
(1:107). 
Examination by testing operations across all of the eight police regions revealed the 
majority of roadside drug tests in the period were undertaken in the highly populated south 
east corner of the state (comprising the North Coast, South Eastern, Metro North and Metro 
South police regions). These four police regions cover 68.0% of the state population and 
cumulatively represent 64.0% of all roadside tests and 65.0% of positive tests (see Table 3). 
The region with the most total detections was South Eastern, followed by North Coast, then 
Southern region.  
3.2. Analysis of positive detections 
Of the cases confirmed positive (N = 2,129), there were 2,057 drug driving offenders 
detected in the period, with males (n = 1,772; 86.1%) considerably more likely to be detected 
than females (n =285, 13.9%).   
Examination of number of detections and vehicle type revealed that most commonly, 
drivers were detected when driving a car, followed by a heavy vehicle, then a motorcycle (see 
Table 4). Examination of the proportion of detections by percentage of vehicles on register in 
Queensland as of June 2012 reveals that heavy vehicles are over-represented.   
Examination of the distribution of positive tests and the detection rate across the days 
of the week revealed that over 75.0% of all tests were conducted between Thursday and 
Sunday; with Saturday resulting in the highest number of positive detections (see Table 5). 
Examination of time of day revealed that while the majority of tests were conducted during 
daylight hours (n = 26,212 between 6.00am to 11.59am; percentage detection = 2.0% and n = 
27,390 between 12.00pm to5.59pm; percentage detection = 2.4%).  However, when 
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represented as a detection rate the period between midnight and 5:59am (n = 7,551 tests) 
resulted in the highest proportion of detections per overall test (4.5%), followed by the period 
between 6.00pm to 11.59pm (n = 19,471 tests; 3.0% detections). 
  
3.3. Frequency of each drug detected  
The frequency of drugs detected by way of oral fluid analysis is displayed in Figure 1. 
It can be seen that the majority of detections involved MA (40.8%), followed by THC 
(29.8%). There were 589 (27.7%) cases of polydrug driving, of which the majority was for 
the combination of MA and THC. 
Examination of drug type detected by year is provided in Table 6. Across all years 
MA was the most common drug detected followed by THC and MA/THC combined. 
Interestingly, the rate of MA detections is twice as high as THC in 2008, whereas in 2009 the 
opposite is true with twice as many THC detections than MA. From 2010 onward this trend 
starts to reverse with MA again being the dominant drug detected. The rate of detection for 
MA/THC combination remained relatively consistent in 2008 and 2010-2012. MDMA and 
MDMA combinations account for a relatively very small number of detections. 
Examination of drug type both between and within each Queensland police region 
was undertaken to determine if there was a different pattern of detection (see Table 7). 
Interestingly, strong regional variations were apparent. Examination within drug type 
revealed that the detection rate for MA to THC was approximately 2:1 in the Central, Metro 
South, South Eastern and Southern regions and approximately 3:1 in the Metro North region. 
Conversely, the detection rate for THC to MA was approximately 4:1 in the Far North region. 
Further, the lowest rate of MA/THC combination was also observed in the Far North 
Queensland police region.  
Examination of drug type by gender revealed that the percentage of MA, MA/THC 
combination, MDMA and MDMA/THC combination detections was greater among females 
than males, whereas the percentage of THC detections was greater among males than females 
(see Figure 2).  
Finally, examination of age revealed that the entire sample ranged from 17 to 63 (M = 
33.19 years; SD = 9.59), with the highest proportion of detections seen in the 30-39 age group 
(32.4%), followed by the 40-49 (20.1%) and 25-29 (19.4%) age groups respectively (see 
Table 8). Examination of type of drug detected reveals an interesting pattern with younger 
cohorts (aged between 17 and 24 years) more often testing positive to THC followed by MA. 
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However as age increases the detection of MA increases to where it becomes clearly the 
dominant detected drug from the age of 25 onwards. The proportion of detection for 
MA/THC combination remains relatively stable from 17 to 49 years of age, where it then 
begins to decrease. Drivers under the age of 30 years were more likely than their older 
counterparts to be detected with MDMA, whether by itself or in combination with other 
drugs.  
4. Discussion 
The purpose of this investigation was to present an overview of roadside drug driving 
enforcement and detections in Queensland, Australia since the introduction of oral fluid 
screening. The roadside oral fluid detection program was introduced on 1 December 2007 
and this is the first study to report on the complete data to date. The results from this 
investigation reveal that roadside oral fluid screening is an effective measure for detecting the 
presence of illicit drugs among motorists. As a result over 2,000 drivers in Queensland have 
been charged with drugged driving under the legislation between 1 December 2007 and 30 
June 2012.  
The three legislated drugs screened for on the roadside were MA, THC and MDMA 
and less than 0.01% of roadside tests were identified by Queensland Government forensic 
laboratory as false positive screens (additional information regarding false positives is 
unavailable due to privacy reasons). Interestingly, the detection rate for drug driving (RDT) 
in each year was higher than the corresponding yearly drink driving (RBT) detection rate. 
The combined detection rate for drug driving over the period for was 1:38, whereas the 
comparative RBT detection rate was 1:107. At first appearance this could indicate there are 
just as many, or substantially more drug drivers on Queensland roads as compared to drink 
drivers. Another possible explanation for the difference in detection rates has to do with the 
saturation enforcement approach to drink driving as opposed to a more targeted approach for 
RDT. For example, while there were approximately 25,000 RDT tests in 2011, there were 
almost 3,000,000 RBT tests in Queensland in the same year. The comparative high rate of 
RDT detections compared to RBT detections is an area for further investigation.  
The overall characteristics of drivers who tested positive to the presence of at least 
one of the target illicit drugs are that they are likely to be male, aged 30-39 years, driving a 
car on Friday, Saturday or Sunday between 6.00pm and 6.00am and testing positive for MA. 
Analysis of the most common drug type detected revealed MA (40.8%) was most prevalent, 
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followed by THC (29.8%) and MA/THC combination (22.5%). By comparison the rate of 
MDMA detection was very low (1.7%). 
As the presence of the three same drugs are tested in a similar manner across all 
Australian jurisdictions, the overall rate and pattern of detection of the current study was 
compared to other jurisdictions where data was available. The detection rate of 2.7% found in 
the current study is higher compared to New South Wales (2.0%; see Rowden et al., 2011), 
South Australia (2.3%; see Thompson, 2008) and Victoria (2.4%; see Drummer at al., 2007); 
whereas the rate of detection in Western Australia is reportedly much higher compared with 
all other jurisdictions at 5.3% (see Woolley and Baldock, 2009). While this variability 
between the jurisdictions is likely reflective of enforcement practices, it is interesting to note 
that the pattern of detection remains the same with the greatest number of detections being 
recorded for MA, followed by THC and combinations with MDMA.  
While the data shows that the most commonly detected drug on the roadside was MA 
the National Drug Household Survey (NDHS) (Australian Institute of Health and Welfare 
[AIHW], 2011) reports that MA is the third most commonly used illicit drug in the 
community (behind Cannabis and Ecstasy) with recent use peaking at 5.9% in the 20-29 year 
age group. Cannabis has consistently been reported in Australia as the most commonly used 
illicit drug with recent use highest in the 18-25 years age group where almost one in five 
report having used at least once in the past year (AIHW, 2011). In the overall analysis of the 
current roadside data, cannabis (THC) was found to be the second most common drug 
detected after MA. Arguably the general prevalence of MA over THC may be an effect of the 
difference in time windows of detection for the two drugs using the current roadside 
technology. Therefore the higher proportions of MA detections may not be reflective of 
usage, in terms of absolute numbers of users in the community, but rather the ability to better 
detect MA as compared to THC via saliva at the roadside. Consequently some drivers may 
not be detected, particularly for THC, when driving with concentration below the sensitivity 
of the cut off threshold for the roadside screening devices (Drummer et al., 2007).  
What is also interesting when roadside detection data is compared to usage patterns 
reported in the NDHS (AIHW, 2011) is the relative low levels of detection of roadside 
MDMA compared to the comparative level of use in the community. The NDHS reports that 
MDMA/Ecstasy is the second most commonly used illicit drug in Australia with recent use 
peaking at just under 10.0% for the 20-29 years age group. However, in this roadside data 
MDMA by itself represented less than 2.0% of total detections. This differentiation may 
represent changed drug use patterns over time, differences between years in which surveys 
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were undertaken, differences between numbers of people reported having ever used MDMA 
and more frequent use of MDMA, or may be a characteristic of different sampling 
methodologies between on the ground road side testing and broader based household 
surveying with comparatively small samples in specific regions. Roadside testing may also be 
more sensitive towards detecting local drug trends and patterns of usage. What is certain is 
that roadside testing can provide immediate local data on consumption behaviours that can be 
compared over time on a regional basis. 
Examination of drug type detected in different police regions revealed an interesting 
pattern where Far Northern Queensland (regional area) showed a detection rate of four THC 
detections for every one MA detection, whereas the more populist metropolitan regions in the 
south east corner of the state returned a detection rate of approximately two MA detections 
for every one THC detection. As such, the location of the roadside drug testing operations 
can have a strong influence on the type of drug detected. Closer examination of the data also 
revealed different patterns associated with age and gender. For males, THC is more likely 
than any other drug to be detected in younger drivers under 25. However in the older male 
age groups MA is the most frequently detected. This pattern is not reflected in the female 
sample where MA consistently ranks as the most common drug detected in all age groups.   
When prevalence rates are examined over time, drug driving detection rates have 
almost doubled from around 2.0% in the early years of roadside testing operations to just 
under 4.0% in the latter years. This increase could be due to a number of factors such as the 
30.0% increase in the number of roadside tests which now cover more of the community 
compared to limited operations in the earlier years of the program. Also, over the years there 
has been an increase in intelligence driven targeting of sites. Finally, the increase may reflect 
an increase in drug driving behaviour across the community. However the data gathered for 
this project is unable to accurately identify any of the above propositions as the major cause.   
One of the results in the data that requires further explanation is related to the number 
of tests carried out at different times of the day. The data provided in table 6 indicates that the 
majority of roadside tests were undertaken between the daytime hours of 6.00am to 5.59pm. 
At first inspection this may seem surprising when one considers the behaviour under 
investigation and the use of intelligence based targeting of testing times and sites would most 
likely suggest operations during the night (6:00pm-11:59pm) and early morning hours 
(midnight-5.59am). After discussions with operational police the artefact of over two thirds 
of tests being conducted during daytime hours (6:00am-5:59pm) is possibly a result of, 
deterrence based testing strategy (i.e. any time of the day), strategic operations with other 
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crime initiatives and resource allocations favouring daylight hours. More significantly, as 
drug testing is carried out by a relatively small number of trained officers, it is likely the 
higher rate of detection during night-time and early morning hours (6:00pm-5:59am) takes 
these officers off the actual roadside screening activity to the more “one on one” time 
intensive activity of processing a positive screened driver. Furthermore there are a number of 
workplace operational and site safety constraints that need to be considered for night 
operations. These safety constraints restrict the number and size of operational sites at which 
RDT can be conducted where sites may be smaller and manned by fewer officers. 
Additionally, RDT and RBT operations are regularly undertaken as joint operations and 
during night operations these multi use sites are more often temporarily closed to incoming 
vehicles (compared to day operations) due to the site saturation of vehicles on the actual 
testing site (i.e. the site is full with no spaces for testing). Conversely, daytime testing 
activities are able to operate on larger sites with greater numbers of operational officers 
which facilitates a larger throughput of drivers. Consequently, while the number of tests 
during night and early morning hours is comparatively much less than daytime hours, the 
detection rate of positive drivers is almost twice that compared to daytime hours.   
In conclusion, the data examined in this research clearly shows that even within the 
context of three illicit substances (THC, MA, MDMA) there are a significant number of drug 
driving apprehensions. While there are a number of debates about types and sensitivities of 
roadside oral fluid testing devices, current technologies can successfully be implemented on 
the roadside and can detect significant numbers of impaired drivers. The data also shows that 
as detection programs have grown over the years so to have the number of drivers 
apprehended. Some could suggest that drug impaired driving is increasing and at levels 
higher than drink driving, although more data would still need to be gathered and examined 
to substantially verify this claim. Unlike drink driving, which can be viewed as a single drug 
type driving offence, the multiple drugs involved in the current drug driving offences 
highlight the importance of regional, age and gender patters of consumption and driving. 
Interestingly, many types of transport including car, heavy vehicle, motorcycle and water 
craft all provided drivers with positive samples. This relatively new data on drug driving 
definitely indicates the need for enforcement, education and prevention and most importantly, 
the need for more research into the behaviour so as to appropriately inform responses and 
interventions.  
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Table 1: Month and year each Australian jurisdiction introduced roadside drug testing 
Australian Jurisdiction Month/Year 
Victoria December 2004 
Tasmania July 2005 
South Australia July 2006 
New South Wales December 2006 
Western Australia October 2007 
Queensland December 2007 
Northern Territory  July 2008 
Australian Capital Territory May 2011 
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Table 2: Roadside drug tests conducted and offences detected by year, 1 December 2007 to 
30 June 2012 
Year of 
detection 
Number of 
roadside tests 
conducted 
Number of 
positive 
roadside 
tests 
% of 
positives per 
year 
Detection 
(%) 
Detection 
rate for RDT 
Comparative 
Queensland 
RBT detection 
rate 
2007 700 18 0.8 2.3 1:39 1:115 
2008 10,747 216 10.1 2.0 1:50 1:97 
2009 12,489 254 11.9 2.0 1:49 1:95 
2010 21,655 440 20.7 2.0 1:49 1:101 
2011 25,172 825 38.8 3.3 1:31 1:123 
2012 9,861 376 17.7 3.8 1:26 1:133 
Total 80,624 2,129 100.0 2.7 1:38 1:107 
Note: 2007 and 2012 are not complete calendar years. 
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Table 3: Roadside drug tests and offences detected by Queensland police region, 1 December 
2007 to 30 June 2012 
Police 
Region 
No. of 
roadside tests 
conducted 
% total tests No. of 
positive 
roadside tests 
% of 
positives 
Queensland 
population as 
at 30 June 
2012 1 
% of 
Queensland 
population 
Central 8,740 10.8 215 10.1 388,887 8.6 
Far Northern 4,895 6.1 143 6.7 267,335 5.9 
Metro North 9,836 12.2 225 10.6 677,433 15.0 
Metro South 8,083 10.0 219 10.3 742,049 18.2 
North Coast 20,144 25.0 467 21.9 824,315 18.2 
Northern 4,514 5.6 123 5.8 276,645 6.1 
South 
Eastern 
13,151 16.3 475 22.3 837,854 18.5 
Southern 11,261 14.0 262 12.3 510,011 11.3 
Total 80,624 100.0 2,129 100.0 4,524,529 100.0 
1 Source: Australian Bureau of Statistics, 2012; Queensland Police Service, Statistical Services  
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Table 4: Positive drug driving offences by vehicle type and percentage of vehicles on register 
Vehicle Type Number of 
detection 
% total 
detections 
% total vehicles on 
register in Queensland  as 
at 30 June 2012 
Car 1765 82.9 91.9 
Heavy Vehicle (>4.5tonne) 265 12.4 4.0 
Motorcycle 84 3.9 3.8 
Watercraft 12 .7 NA 
Bus 3 .1 0.3 
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Table 5: Number of roadside drug tests conducted by day of week 
Day of week 
Number of roadside 
tests conducted 
Number of positive 
roadside tests 
% of positives per 
day of week 
Detection (%) 
Monday 6,749 127 6.0 1.9 
Tuesday 9,279 159 7.5 1.7 
Wednesday 10,990 231 10.9 2.1 
Thursday 13,177 336 15.8 2.6 
Friday 12,756 368 17.2 2.9 
Saturday 14,017 511 24.0 3.7 
Sunday 13,656 397 18.6 2.9 
Total 80,624 2,129 100.0 2.7 
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Figure 1: Frequency of positive tests by drug type  
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Table 6: Proportion of positive tests by drug type for the period 2007-2012 and the 
percentage of drug detected each year (in parenthesis). 
 Year 
Drug Type 2007 (%) 2008 (%) 2009 (%) 2010 (%) 2011 (%) 2012 (%) Total (%) 
MA 
 
12 
(1.4) 
(66.7) 
80 
(9.2) 
(37.0) 
55 
(6.3) 
(21.7) 
160 
(18.4) 
(36.4) 
372 
(42.8) 
(45.1) 
190 
(21.9) 
(50.5) 
869 
(100) 
(40.8) 
THC 
 
1 
(0.2) 
(5.6) 
40 
(6.3) 
(18.5) 
129 
(20.3) 
(50.8) 
155 
(24.4) 
(35.2) 
227 
(35.8) 
(27.5) 
82 
(12.9) 
(21.8) 
634 
(100) 
(29.8) 
MA/THC 
 
1 
(0.2) 
(5.6) 
57 
(11.9) 
(26.4) 
43 
(9.0) 
(16.9) 
101 
(21.0) 
(23.0) 
194 
(40.4) 
(23.5) 
84 
(17.5) 
(22.3) 
480 
(100) 
(22.5) 
MDMA/THC 
 
0 
(0.0) 
(0.0) 
15 
(36.6) 
(6.9) 
5 
(12.2) 
(2.0) 
4 
(9.8) 
(0.9) 
11 
(26.8) 
(1.3) 
6 
(14.6) 
(1.6) 
41 
(100) 
(1.9) 
MDMA 
 
2 
(5.4) 
(11.1) 
8 
(21.6) 
(3.7) 
9 
(24.3) 
(3.5) 
6 
(16.2) 
(1.4) 
11 
(29.7) 
(1.3) 
1 
(2.7) 
(0.3) 
37 
(100) 
(1.7) 
MA/MDMA 
 
1 
(2.8) 
(5.6) 
7 
(19.4) 
(3.2) 
6 
(16.7) 
(2.4) 
8 
(22.2) 
(1.8) 
6 
(16.7) 
(0.7) 
8 
(22.2) 
(2.1) 
36 
(100) 
(1.7) 
MA/MDMA/THC 
 
1 
(3.1) 
(5.6) 
9 
(28.1) 
(4.2) 
7 
(21.9) 
(2.8) 
6 
(18.8) 
(1.4) 
4 
(12.5) 
(0.5) 
5 
(15.6) 
(1.3) 
32 
(100) 
(1.5) 
Age Group Total 
 
18 
(0.8) 
(100) 
216 
(10.1) 
(100) 
254 
(11.9) 
(100) 
440 
(20.7) 
(100) 
825 
(38.8) 
(100) 
376 
(17.7) 
(100) 
2,129 
(100) 
(100) 
Note: 2007 and 2012 are not complete calendar years. 
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Table 7: Proportion of positive tests by drug type across the Queensland police regions and 
percentage of drug type detected within each region (in parenthesis). 
 QPS Region 
Drug  
Type 
CR (%) FNR (%) MNR (%) MSR (%) NCR (%) NR (%) SER (%) SR (%) Total (%)
MA 
 
114 
(13.1) 
(53.0) 
20 
(2.3) 
(14.0) 
108 
(12.4) 
(48.0) 
95 
(10.9) 
(43.4) 
169 
(19.4) 
(36.2) 
44 
(5.1) 
(35.8) 
200 
(23.0) 
(42.1) 
119 
(13.7) 
(45.4) 
869 
(100) 
(40.8) 
THC 
 
49 
(7.7) 
(22.8) 
91 
(14.4) 
(63.6) 
33 
(5.7) 
(14.7) 
49 
(7.7) 
(22.4) 
163 
(25.7) 
(34.9) 
51 
(8.0) 
(41.5) 
124 
(19.6) 
(26.1) 
74 
(11.7) 
(28.2) 
634 
(100) 
(29.8) 
MA/THC 
 
47 
(9.8) 
(21.9) 
22 
(4.6) 
(15.4) 
59 
(12.3) 
(26.2) 
49 
(10.2) 
(22.4) 
100 
(21.4) 
(21.4) 
22 
(4.6) 
(17.9) 
124 
(25.8) 
(26.1) 
57 
(11.9) 
(21.8) 
480 
(100) 
(22.5) 
MDMA/ 
THC 
3 
(7.3) 
(1.4) 
6 
(14.6) 
(4.2) 
3 
(7.3) 
(1.3) 
6 
(14.6) 
(2.7) 
11 
(26.8) 
(2.4) 
3 
(7.3) 
(2.4) 
3 
(7.3) 
(0.6) 
6 
(14.6) 
(2.3) 
41 
(100) 
(1.9) 
MDMA 0 
(0.0) 
(0.0) 
3 
(8.1) 
(2.1) 
10 
(27.0) 
(4.4) 
6 
(16.2) 
(2.7) 
11 
(29.7) 
(2.4) 
2 
(5.4) 
(1.6) 
4 
(10.8) 
(0.8) 
1 
(2.7) 
(0.4) 
37 
(100) 
(1.7) 
MA/ 
MDMA 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
10 
(27.8) 
(4.4) 
7 
(19.4) 
(3.2) 
8 
(22.2) 
(1.7) 
0 
(0.0) 
(0.0) 
8 
(22.2) 
(1.7) 
3 
(8.3) 
(1.1) 
36 
(100) 
(1.7) 
MA/ 
MDMA/ 
THC 
2 
(6.3) 
(0.9) 
1 
(3.1) 
(0.7) 
2 
(6.3) 
(0.9) 
7 
(21.9) 
(3.2) 
5 
(15.6) 
(1.1) 
1 
(3.1) 
(0.8) 
12 
(37.5) 
(2.5) 
2 
(6.3) 
(0.8) 
32 
(100) 
(1.5) 
QPS 
Region 
Total  
215 
(10.1) 
(100) 
143 
(6.7) 
(100) 
225 
(10.6) 
(100) 
219 
(10.3) 
(100) 
467 
(21.9) 
(100) 
123 
(5.8) 
(100) 
475 
(22.3) 
(100) 
262 
(12.3) 
(100) 
2,129 
(100) 
(100) 
Note: CR = Central Region. FNR = Far Northern Region. MNR = Metro North Region. MSR = Metro South Region. NCR = North Coast 
Region. NR = Northern Region. SER = South Eastern Region. SR = Southern Region.  
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Figure 2: Frequency of positive tests by drug type and gender 
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Table 8: Proportion of positive tests by drug type and age group and the percentage of drug 
type detected within each age cohort (in parenthesis). 
 Age Group 
Drug 
Detected 
17-19 (%) 20-24 (%) 25-29 (%) 30-39 (%) 40-49 (%) 50-59 (%) 60+ (%) Total (%) 
MA 
 
24 
(2.8) 
(15.6) 
98 
(11.3) 
(32.3) 
161 
(18.5) 
(38.9) 
321 
(36.9) 
(46.6) 
207 
(23.8) 
(46.1) 
52 
(6.0) 
(48.1) 
6 
(0.7) 
(50.0) 
869 
(100) 
(40.8) 
THC 
 
69 
(10.9) 
(44.8) 
101 
(15.9) 
(33.3) 
122 
(19.2) 
(29.5) 
179 
(28.2) 
(26.0) 
124 
(19.6) 
(27.6) 
34 
(5.4) 
(31.5) 
5 
(0.8) 
(41.7) 
634 
(100) 
(29.8) 
MA/THC 
 
36 
(7.5) 
(23.4) 
69 
(14.4) 
(22.8) 
86 
(17.9) 
(20.8) 
160 
(33.3) 
(23.2) 
109 
(22.7) 
(24.3) 
19 
(4.0) 
(17.6) 
1 
(0.2) 
(8.3) 
480 
(100) 
(22.5) 
MDMA/THC 
 
9 
(22.0) 
(5.8) 
13 
(31.7) 
(4.3) 
10 
(24.4) 
(2.4) 
6 
(14.6) 
(0.9) 
0 
(0.0) 
(0.0) 
3 
(7.3) 
(2.8) 
0 
(0.0) 
(0.0) 
41 
(100) 
(1.9) 
MDMA 
 
9 
(24.3) 
(5.8) 
9 
(24.3) 
(3.0) 
12 
(32.4) 
(2.9) 
7 
(18.9) 
(1.0) 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
37 
(100) 
(1.7) 
MA/MDMA 
 
2 
(5.6) 
(1.3) 
6 
(16.7) 
(2.0) 
16 
(44.4) 
(3.9) 
7 
(19.4) 
(1.0) 
5 
(13.9) 
(1.1) 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
36 
(100) 
(1.7) 
MA/MDMA/
THC 
 
5 
(15.6) 
(3.2) 
7 
(21.9) 
(2.3) 
7 
(21.9) 
(1.7) 
9 
(28.1) 
(1.3) 
4 
(12.5) 
(0.9) 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
32 
(100) 
(1.5) 
Age Group 
Total 
154 
(7.2) 
(100) 
303 
(14.2) 
(100) 
414 
(19.4) 
(100) 
689 
(32.4) 
(100) 
449 
(21.1) 
(100) 
108 
(5.1) 
(100) 
12 
(0.6) 
(100) 
2,129 
(100) 
(100) 
 
